期刊文献+

艾塞那肽对非酒精性脂肪肝大鼠肝脏NF-κB、TNF-α、TGF-β_1表达的影响 被引量:16

Effect of exenatide on the expressions of liver NF-κB,TNF-α and TGF-β_1 in rats with non-alcoholic fatty liver disease
原文传递
导出
摘要 目的观察艾塞那肽(Exenatide)对高脂诱导大鼠非酒精性脂肪性肝病(NAFLD)的作用。方法建立SD大鼠NAFLD模型(HF组),高脂喂养SD大鼠8周后予艾塞那肽(10μg/kg)干预8周(HF+Exe组),观察肝脏病理变化及相关检测。结果 HF+Exe组大鼠体重、肝指数(肝湿重/大鼠体重)、肝脏TG、FFA、OGTT、2hPG、FIns、胰岛素抵抗指数(HOMA-IR)、TG、LDL-C、丙氨酸转氨酶(ALT)较HF组明显下降(P<0.01或P<0.05);HF组大鼠存在明显肝脏脂肪沉积,HF+Exe组大鼠肝脏脂肪沉积明显减少(P<0.01);HF+Exe组肝脏核转录因子(NF-κB)、肿瘤坏死因子-α(TNF-α)、转化生长因子-β1(TGF-β1)mR-NA表达较HF组明显下降(P<0.05)。结论艾塞那肽改善高脂诱导大鼠糖脂代谢、肝功能、减少肝脏NF-κB、TNF-α、TGF-β1表达,对NAFLD有一定防治作用。 Objective To investigate the effect of exenatide on expresions of 1iver NF-κB,TNF-α and TGF-β1 in rats with non-alcoholic fatty liver disease(NAFLD).Methods The high fat diet-induced NAFLD rat models were established(group HF).After the high fat diet for 8 weeks,the rats were given exenatide(10 μg/kg) intervention for 8 weeks(group HF+Exe).Observations on the hepatic pathological changes and other related inspections were performed for studying the effect of treatment.Results The body weight,liver index(liver weight / rat weight),liver triglyceride(TG),serum free fatty acid(FFA),2 hours serum glucose after oral glucose tolerance test(OGTT),serum fasting insulin(FIns),insulin resistance index(HOMA-IR),serum TG,low density lipoprotein cholesterol(LDL-C),and serum alanineaminotransferase(ALT) were all significantly lowered in the group HF+Exe than in the group HF(P〈0.01,P〈0.05).In the group HF,there appeared a significant steatosis,whilst the steatosis was significantly improved in group HF+Exe(P〈0.01).mRNA expression levels of nuclear factor-κB(NF-κB),tumor necrosis factor-α(TNF-α),and transforming growth factor-β1(TGF-β1) in liver were significantly decreased in the group HF+Exe than in the group HF(P〈0.01).Conclusion Exenatide improves the glucose and lipid metabolisms,restores the liver function,and decreases expressions in the liver NF-κB,TNF-α,and TGF-β1 in high fat diet rats,thus preventing the occurrence and progression of NAFLD in rats.
出处 《中国糖尿病杂志》 CAS CSCD 北大核心 2012年第10期771-774,共4页 Chinese Journal of Diabetes
基金 江苏省自然基金项目(BK200861) 南京市医学科技发展项目(YKK11092)
关键词 艾塞那肽 非酒精性脂肪肝 炎症因子 大鼠 Exenatide Non-alcoholic fatty liver Inflammatory factor Rats
  • 相关文献

参考文献7

  • 1Liu X, Hu H, Yin JQ. Therapeutic strategies agdinst TGF- beta signaling pathway in hepatic fibrosis. Liver Int, 2006, 26 : 8-22.
  • 2Feldstein AE, Werneburg NW, Canbay A, et al. Free fatty acids promote hepatic lipotoxicity by stimulating TNF- aexpression via a lysosomal pathway. Hepatology, 2004, 40: 185-194.
  • 3Salehi M, Aulinger BA, D' Alessio DA. Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev, 2008, 29 : 367-379.
  • 4Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in oh/oh mice. Hepatology, 2006, 43:173-181.
  • 5Gupta NA, Mells J, Dunham RM, et al. Glucagon-like pep- tide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating ele- ments of the insulin signaling pathway. Hepatology, 2010, 51: 1584-1592.
  • 6冯文焕,汪大望,郑景晨,高鑫,沈飞霞,吴步猛,何秋香,袁谦,朱大龙.罗格列酮联合二甲双胍对肥胖大鼠脂肪肝的防治作用[J].江苏医药,2009,35(12):1470-1472. 被引量:11
  • 7矫杰,李雅君,李晓沛,张彦,蔡瑾.罗格列酮预防非酒精性脂肪性肝炎大鼠肝纤维化的研究[J].中国糖尿病杂志,2011,19(1):55-59. 被引量:3

二级参考文献21

共引文献12

同被引文献161

引证文献16

二级引证文献124

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部